Pfizer News and Updates

Name: Latest research reports of Pfizer Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Pfizer Ltd.
Rating: 4
Author: ICICI Securities Limited

Keep track of all breaking news on Pfizer from all sources in a single place.

Load latest

Pfizer Ltd.

26 Jun 2023

4972.50

-0.44%

Pfizer to discontinue development of obesity drug due to side effects

Business Standard

Pfizer has been developing treatments to target weight loss in diabetes and obesity patients, as it races to target a market estimated to reach $100 billion by the end the of decade

Pfizer Ltd. is trading below its 30 day SMA of 5101.6

Pfizer Ltd.

25 Jun 2023

4972.50

-0.44%

'Govt kept same rules for Indian, foreign cos while getting Covid vaccines'

Business Standard

Foreign-made vaccines were not procured during the Covid pandemic as the firms were demanding indemnity, which was not made available to Indian vaccine manufacturers, Union Health Minister Mansukh Mandaviya has said, asserting that the "same rule applies for all". He also said that it was wrong to suggest that India stopped foreign made vaccines like that made by Moderna and Pfizer from coming to India. "We may have certain requirements and strengths and other countries may have some other strengths and needs. It is wrong to say that India stopped any country from coming to India.When they applied with required data, we gave them emergency use approvals just like we gave to Indian companies," Mandaviya said in an exclusive interview to PTI recently. However, their demands for indemnification and sovereign immunity waivers were a major impediment and eventually the government did not go ahead with it, the minister stated. "At that time, Sputnik vaccine was also there and so were Ind

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

12 Jun 2023

4972.50

-0.44%

BioNTech faces several lawsuits in Germany over Covid vaccine side effects

Business Standard

German drug company BioNTech is facing hundreds of lawsuits, worth one million euros, in country for alleged health damage due to its Covid-19 vaccine, co-developed with American pharma giant Pfizer

Pfizer Ltd. is trading below its 30 day SMA of 5101.6

Pfizer Ltd.

07 Jun 2023

4972.50

-0.44%

Moderna, Pfizer hit with new patent lawsuits over COVID vaccines

Moneycontrol

The lawsuits add to a web of patent disputes between biotech companies over technology used in the coronavirus shots, including a case brought last year in Massachusetts by Moderna against Pfizer and its partner BioNTech.

Pfizer Ltd. is trading above its 200 day SMA of 4947.9

Pfizer Ltd.

26 May 2023

4972.50

-0.44%

Covid pill Paxlovid gets full FDA approval after a year of emergency use

Business Standard

Pfizer received full approval on Thursday for its COVID-19 pill Paxlovid that's been the go-to treatment against the coronavirus. More than 11 million prescriptions for Paxlovid have been dispensed since the Food and Drug Administration allowed emergency use in late 2021. The emergency status was based on early studies and was intended to be temporary pending follow-up research. The FDA granted full approval for adults with COVID-19 who face high risks of severe disease, which can lead to hospitalization or death. That group typically includes older adults and those with common medical conditions like diabetes, asthma and obesity. The decision allows Pfizer's drug to remain on the market indefinitely and to be marketed similarly to other drugs. The pill is still available for children ages 12 to 17 under a separate emergency authorisation. The US government has stockpiled millions of doses of Paxlovid and patients will continue to receive it at no charge, the FDA said in a stateme

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Pfizer Ltd.

18 May 2023

4972.50

-0.44%

Pfizer suspends sale of three antibiotics in India over technical issues

Business Standard

Investigating matter with contract manufacturer Astral Steritech, says pharma firm

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Pfizer suspends sale, use of some products in India over quality concerns

Business Standard | 18 May 2023

Pfizer Ltd.

17 May 2023

4972.50

-0.44%

Power brands help restore revenue traction

Accumulate: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Q4FY23 marked a turnaround in Pfizer’s performance as the declining revenue trend (down 7% in FY23) was arrested in Q4, which saw a 4% YoY rise. The turnaround was driven by traction in key brands such as Magnex, Corex DX, Dolonex, Minipress XL and Prevenar-13.

ICICI Securities Limited upgraded Pfizer Ltd. to Buy with a price target of 6100.0 on 14 Nov, 2025.

Pfizer Ltd.

16 May 2023

4972.50

-0.44%

Pfizer Ltd

Hold: Pfizer Ltd.

Target

ICICI Direct

Pfizer Ltd. is trading below its 30 day SMA of 5101.6

Pfizer Ltd.

15 May 2023

4972.50

-0.44%

Pfizer Standalone March 2023 Net Sales at Rs 572.64 crore, up 4.18% Y-o-Y

Moneycontrol

ICICI Securities Limited upgraded Pfizer Ltd. to Buy with a price target of 6100.0 on 14 Nov, 2025.

Pfizer consolidated net profit rises 3% to Rs 130 crore in March quarter

Business Standard | 15 May 2023 2 more

Pfizer Ltd.

11 May 2023

4972.50

-0.44%

Pfizer pouring windfall profits from Covid-19 vaccine into cancer battle

Business Standard

The U.S. government will end the COVID Public Health Emergency on Thursday that allowed millions of Americans to receive vaccines, tests and treatments at no cost